News

3 Reasons to Sell CSL and 1 Stock to Buy Instead

Over the past six months, Carlisle’s stock price fell to $343.26. Shareholders have lost 14.9% of their capital, which is disappointing considering the S&P 500 has climbed by 7.6%. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and might have investors contemplating their next move.